Cabaletta Bio is a late-stage clinical biotechnology company uniquely positioned to pioneer the transition of CD19-directed CAR-T cell therapies from oncology into the multi-billion dollar autoimmune market. Its lead asset, rese-cel (resecabtagene autoleucel), has demonstrated exceptional clinical efficacy, achieving durable, immunomodulator-free responses up to 1.5 years in refractory myositis patients. By securing a 10-year automated manufacturing agreement with Cellares and advancing preconditioning-free (PC-free) regimens, Cabaletta is systematically addressing the key commercial bottlenecks of autologous cell therapies—scalability, high cost of goods, and intensive inpatient preconditioning. While the company's pre-revenue status and historical going-concern warnings present near-term risks, the successful $150 million capital raise in May 2026 extends its cash runway into mid-2027, providing a solid runway to achieve pivotal clinical readouts and transition into a commercial-stage leader.